维立志博连续两年入选_老虎社区_美港股上老虎

维立志博连续两年入选ASCO口头报告，还是针对全球缺乏疗法的癌种，比单纯发摘要分量重多了

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":449350910866040,"tweetId":"449350910866040","gmtCreate":1750731522795,"gmtModify":1750731523823,"author":{"id":4209807600629590,"idStr":"4209807600629590","authorId":4209807600629590,"authorIdStr":"4209807600629590","name":"芝士财富","avatar":"https://static.tigerbbs.com/7fe83d1c672106eb11674af49f16978f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body>维立志博连续两年入选ASCO口头报告，还是针对全球缺乏疗法的癌种，比单纯发摘要分量重多了</body></html>","htmlText":"<html><head></head><body>维立志博连续两年入选ASCO口头报告，还是针对全球缺乏疗法的癌种，比单纯发摘要分量重多了</body></html>","text":"维立志博连续两年入选ASCO口头报告，还是针对全球缺乏疗法的癌种，比单纯发摘要分量重多了","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/449350910866040","repostId":0,"isVote":1,"tweetType":1,"viewCount":486,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":82,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}